San Diego, CA (Press Release) – Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an inno­va­tive immuno­therapy com­pany, announced today that the first patients were dosed in a Phase 1 study to eval­u­ate the safety and efficacy of CD38 CAR-T ther­apy in re­lapsed or refractory multiple myeloma patients at two clin­i­cal sites – University of Pennsylvania (UPenn) in Philadelphia and Roger Williams Medical Center in Rhode Island. The CD38 CAR-T cells manu­fac­tured at both Sorrento cGMP facilities (San Diego, CA and Providence, RI) met all release specifications and were used in the study.

This study is the first US-based clin­i­cal trial targeting CD38 using an au­tol­o­gous CAR-T cell ther­apy. Details on the study can be found at: www.clinicaltrials.gov : NCT03464916. Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma.

About Sorrento Therapeutics, Inc.

Sorrento is a clin­i­cal stage, anti­body-centric, bio­pharma­ceu­tical com­pany devel­op­ing new ther­a­pies to turn malignant cancers into man­ageable and possibly curable diseases. Sorrento's multimodal multi­pronged ap­proach to fighting cancer is made possible by its’ extensive immuno-oncology plat­forms, in­­clud­ing key assets such as clin­i­cal stage fully human anti­bodies (“G-MAB™ library”), immuno-cellular ther­a­pies (“CAR-T”), anti­body-drug con­ju­gates (“ADC”), and oncolytic virus (“Seprehvir®”).

Sorrento's commitment to life-enhancing ther­a­pies is also dem­onstrated by our effort to ad­vance a first-in-class (TRPV1 agonist) non-opioid pain man­agement small molecule in Resiniferatoxin (“RTX”) as well as to promote newly-launched ZTlido™. Resiniferatoxin is com­plet­ing a Phase 1b trial in terminal cancer patients as well as in trial for osteoarthritis (OA) pain man­agement. ZTlido was approved by the FDA on February 28, 2018 for the treat­ment of post-herpetic neuralgia.

For more in­­for­ma­tion visit www.sorrentotherapeutics.com

Forward-Looking Statements

This press release con­tains forward-looking state­ments related to Sorrento Therapeutics, Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and un­cer­tain­ties that could cause actual results to differ materially from those pro­jected. Forward looking state­ments in­clude state­ments regarding the devel­op­ments of and pros­pects for Sorrento's and its sub­sid­i­aries’ and affiliates’ prod­ucts and tech­nolo­gies, in­­clud­ing their re­spec­tive­ anti­body and CAR-T prod­ucts and tech­nolo­gies (including, but not limited to, CD38 CAR-T cell ther­apy pro­gram), and ex­pec­ta­tions for Sorrento's and its sub­sid­i­aries', affiliates’ and joint ventures’ tech­nolo­gies and prod­uct can­di­dates. Risks and un­cer­tain­ties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking state­ments, in­clude, but are not limited to: risks related to Sorrento's, its sub­sid­i­aries', affiliates’ and partners’ tech­nolo­gies and prospects; clin­i­cal devel­op­ment risks, in­­clud­ing risks in the progress, timing, cost, and results of clin­i­cal trials and prod­uct devel­op­ment pro­grams; risks that prior clin­i­cal results and out­comes will not be replicated; risks of dif­fi­culties or delays in obtaining regu­la­tory approvals; risks that clin­i­cal study results may not meet any or all end­points of a clin­i­cal study and that any data generated from such studies may not sup­port a regu­la­tory sub­mission or approval; risks related to seeking regu­la­tory approvals and conducting clin­i­cal trials; risks of supplying drug prod­uct; risks related to Sorrento's ability to leverage the expertise of its employees, sub­sid­i­aries, affiliates and partners to assist the com­pany in the execution of its strategies; risks related to Sorrento's M&A and licensing strategy; risks related to Sorrento’s and its’ sub­sid­i­aries’ abilities to supply drug prod­uct; and other matters that are described in Sorrento's Annual Report on Form 10-K for the year ended December 31, 2017, and sub­se­quent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Com­mis­sion, in­­clud­ing the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking state­ments, which speak only as of the date of this release and we under­take no obli­ga­tion to update any forward-looking state­ment in this press release except as required by law.

Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
ZTlido™ and G-MAB™ are trademarks owned by Scilex Pharma­ceu­ticals, Inc. and Sorrento, re­spec­tive­ly.
Seprehvir® is a registered trademark of Virttu Biologics Limited, a wholly-owned sub­sid­i­ary of TNK Therapeutics, Inc. and part of the group of com­pa­nies owned by Sorrento Therapeutics, Inc.
All other trademarks are the property of their re­spec­tive­ owners.

Source: Sorrento Therapeutics.